UCL 2077

Discontinued Product

UCL 2077 (Cat. No. 2661) has been withdrawn from sale for commercial reasons.
Description: Slow afterhyperpolarization (sAHP) channel blocker; sub-type selective Kv channel effects
Chemical Name: N-Trityl-3-pyridinemethanamine
Purity: ≥99% (HPLC)
Citations (2)
Reviews (1)
Literature (2)

Biological Activity for UCL 2077

UCL 2077 is a slow afterhyperpolarization (sAHP) channel blocker; reduces sAHP in hippocampal slice preparations. Displays no effect on Ca2+ currents or the time course of sAHP/sIAHP. Exhibits potent inhibition of KCNQ1 and KCNQ2, but differential effects at other KCNQs. Rescues memory retrieval in dopamine β-hydroxylase knockout mice.

Technical Data for UCL 2077

M. Wt 350.46
Formula C25H22N2
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 918311-87-2
PubChem ID 24868317
Smiles C(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CN=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for UCL 2077

References are publications that support the biological activity of the product.

Shah et al (2006) Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077). Mol.Pharmacol. 70 1494 PMID: 16877678

Zhang et al (2013) The slow afterhyperpolarization: a target of β1-adrenergic signaling in hippocampus-dependent memory retrieval. J.Neurosci. 33 5006 PMID: 23486971

Soh and Tzingounis (2010) The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol.Pharmacol. 78 1088 PMID: 20843955

View Related Products by Product Action

View all Calcium-Activated Potassium (KCa) Channel Blockers

Keywords: UCL 2077, UCL 2077 supplier, Slow, hyperpolarization, sAHP, channels, blockers, Potassium, KCa, Channels, ca2+-activated, ca2+-dependent, K+, UCL2077, Ca2+-Activated, Voltage-Gated, 2661, Tocris Bioscience

2 Citations for UCL 2077

Citations are publications that use Tocris products. Selected citations for UCL 2077 include:

Paz et al (2018) Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac. Neuropharmacology 137 309 PMID: 29758221

Zhang et al (2013) The slow afterhyperpolarization: a target of β1-adrenergic signaling in hippocampus-dependent memory retrieval. J Neurosci 33 5006 PMID: 23486971

Reviews for UCL 2077

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used UCL 2077?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

UCL 2077 in BK channel study.
By Anonymous on 12/03/2018
Assay Type: In Vitro
Species: Human

UCL 2077 has been used in our lab for assessing its blocking capacity in BK channels. the results were reliable and reproducible. Great product and will purchase again.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Ion Channel Product Listing

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.